Impel Pharmaceuticals To Present At The JMP Securities Life Sciences Conference
Get Alerts IMPL Hot Sheet
Join SI Premium – FREE
SEATTLE, June 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that Adrian Adams, Chairman and Chief Executive Officer, will present a company overview at the JMP Securities Life Sciences Conference on Wednesday, June 15, 2022 at 2:00 p.m. ET in New York, New York.
A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/. A replay of the presentation will be available on the website for 90 days.
About Impel Pharmaceuticals Impel Pharmaceuticals is a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. Impel offers and is developing treatments that pair its proprietary POD® technology with well-established therapeutics. In addition to Trudhesa® nasal spray, which is approved in the U.S. for the acute treatment of migraine with or without aura in adults, Impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism.
For additional information about Impel, please visit www.ImpelPharma.com
Contact:
Media Relations:Melyssa WeibleElixir Health Public RelationsPhone: (1) 201-723-5805Email: [email protected]
Investor RelationsChristina TartagliaStern Investor RelationsPhone: 212-362-1200Email: [email protected]
Source: Impel Pharmaceuticals
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Crypto News: Pepeto DeFi Exchange Nears Launch Following Audit Completion and Final Testing Phase
- Zenith Education Presents Modernized Global Admissions Model and Reports 100% Top Three Acceptance Record
- XRP Price Prediction: Pepeto Presale Targets What XRP’s Ceiling Cannot Deliver
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
JMP SecuritiesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share